Parkinson s Disease in 60 minutes. Dr. Claire Hinnell Movement Disorder Neurologist Director Movement Disorder Clinic JPOCSC

Similar documents
10th Medicine Review Course st July Prakash Kumar

Best Medical Treatments for Parkinson s disease

Optimizing Clinical Communication in Parkinson s Disease:

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

Treatment of Parkinson s Disease: Present and Future

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

Medication Management & Strategies When the levodopa honeymoon is over

Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University

Parkinson s Disease. Gillian Sare

The PD ExpertBriefing: Parkinson s Disease and its Treatment: Secrets, Myths, and Misconceptions

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder

Movement Disorders: A Brief Overview

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

Parkinson s Disease Current Treatment Options

Medications used to treat Parkinson s disease

Dr Barry Snow. Neurologist Auckland District Health Board

Prior Authorization with Quantity Limit Program Summary

Evaluation and Management of Parkinson s Disease in the Older Patient

The Shaking Palsy of 1817

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s

Communicating About OFF Episodes With Your Doctor

PARKINSON S MEDICATION

PD: Key Treatment Considerations

PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.

Drug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.)

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

Advanced Therapies for Motor Symptoms in PD. Matthew Boyce MD

Recent Advances in the cause and treatment of Parkinson disease. Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL

TRANSPARENCY COMMITTEE OPINION. 18 March 2009

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

Drugs used in Parkinsonism

REFERENCE CODE GDHC392DFR PUBLICATION DATE M ARCH 2014 STALEVO/COMTAN (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022

Headway Victoria Epilepsy and Parkinson s Centre

Welcome and Introductions

Objectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.

Clinical Features and Treatment of Parkinson s Disease

The PD You Don t See: Cognitive and Non-motor Symptoms

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Parkinson's Disease KP Update

Parkinson s Disease Medications: Professionals Edition

Parkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust

REFERENCE CODE GDHC395DFR PUBLICAT ION DATE M ARCH 2014 APOKYN (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC237CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022

Faculty. Joseph Friedman, MD

THE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE

Update on Parkinson s disease and other Movement Disorders October 2018

Section 1: What is Parkinson s? Parkinson's Disease Webinar 4/27/2012. April 27th, :00-1:00 PM EST

Depression & Anxiety. What can I do? What are other possible treatments? What is this? Why does this happen? KEY POINTS

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS

Parkinson's Disease and how you can make a difference with medication

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

Welcome and Introductions

Drugs Affecting the Central Nervous System

Key Concepts and Issues in Parkinson s Disease in 2016

WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019

REFERENCE CODE GDHC235CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - US DRUG FORECAST AND MARKET ANALYSIS TO 2022

Issues for Patient Discussion

Understanding Parkinson s Disease Important information for you and your loved ones

Moving fast or moving slow: an overview of Movement Disorders

What is the best medical therapy for early Parkinson's disease? Medications Commonly Used for Parkinson's Disease

Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016

ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM

Motor Fluctuations in Parkinson s Disease

Re-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.

New Medicines Committee Briefing July 2011

Alison Charleston 1 st September 2016

Amantadine Extended-Release. Gocovri, Osmolex ER. Description

What s new for diagnosing and treating Parkinson s Disease?

Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product

Parkinson s Disease. Sirilak yimcharoen

Cardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.

BORDEAUX MDS WINTER SCHOOL FOR YOUNG

A Four Point Plan for Enhanced Support for Parkinson s Disease In B.C.

Continuous dopaminergic stimulation

Parkinson s Disease Update. Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015

What is Parkinson s Disease?

Parkinson s disease: diagnosis and current management

REFERENCE CODE GDHC397DFR PUBLICAT ION DATE M ARCH 2014 NOURIAST (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC401DFR PUBLICAT ION DATE M ARCH 2014 RYTARY/IPX066 (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022

Clinical Guideline for the management of inpatients with Parkinson s disease

Pharmacological treatment of Parkinson's disease

PARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information

REFERENCE CODE GDHC391DFR PUBLICAT ION DATE M ARCH 2014 DUODOPA (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD

Commonly encountered medications and their side effects - what the generalist needs to know

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

PARKINSON S DISEASE OVERVIEW, WITH AN EMPHASIS ON PHYSICAL WELLBEING. Gillian Quinn MISCP, Senior Physiotherapist in Neurology, SVUH

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)

REFERENCE CODE GDHC398DFR PUBLICAT ION DATE M ARCH 2014 SAFINAMIDE (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022

Advances in Parkinson s Disease Treatment. Ryan J. Uitti, M.D. Professor of Neurology Mayo Clinic, Jacksonville, FL

Novel approaches to the pharmacological treatment of Parkinson s disease. Peter Jenner King s College UK

CE on SUNDAY Newark, NJ October 18, 2009

Non-Motor Symptoms of Parkinson s Disease

Strategies for Improving Outcomes in Patients with Parkinson s Disease

Chapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis

Transcription:

Parkinson s Disease in 60 minutes Dr. Claire Hinnell Movement Disorder Neurologist Director Movement Disorder Clinic JPOCSC S

Plan of attack S What causes Parkinson s disease brief S Symptoms/Diagnostic Criteria S Treatment options the whole gammut

Parkinson s Disease

Symptoms

Wearing off Delayed on Increasing dyskinesias

Treatment

Treatment 1. Medications for PD 2. Don t forget the non-motor symptoms 3. Alternative treatments 4. It s not all about medications

Major Medication Classes DOPAMINE Levodopacarbidopa/Sinemet Levodopabenserazide/Prolopa DOPAMINE AGONISTS Pramipexole/Mirapex Ropinirole/Requip Bromocriptine MAOB-I Rasagiline/Azilect Selegiline

Add on Medications Entacapone/ Comtan Amantadine Trihexiphenidyl /Artane

The levodopa myths

Myth S Sinemet accelerates disease progression S Reality: Levodopa has been shown to increase lifespan and dramatically improve quality of life.

Myth S Sinemet stops working after 5 years so we need to save it for later S Reality: Levodopa works for decades. Levodopa does not treat all of the symptoms of PD, but it dramatically helps many of the most disabling motor symptoms.

Myth S Sinemet causes dyskinesias so we need to try to delay the use of Sinemet as long as possible. S Reality: Treatment related side effects are less with levodopa.

Myth S You should wait as long as possible to take the next dose of levodopa. S Reality: Levodopa is most effective when taken on time, just before the previous dose wears off. S Secret: A medication timer can help.

Approach to starting Younger Older, cognitive impairment more emphasis on long-term considerations to guide early treatment longer life expectancy and are more likely to develop motor fluctuations and dyskinesias less emphasis is placed on long-term considerations focus is on providing adequate symptomatic benefit in the near term, with as few adverse effects as possible

In a nutshell S levodopa more robust effect S DA generally more side effects which increase with age (somnolence, hallucinations, peripheral edema, ICD) S motor complications occur earlier with levodopa

Wearing off Delayed on Increasing dyskinesias l-dopa MAOB-I DA** higher dose increased frequency l-dopa DA COMT-I MAOB-I DBS continuous intraduodenal infusion

Deep Brain Stimulation

Duodopa

Recent updates S Tasigna/Nilotinib leukemia drug S Antimalaria drugs (ex: chloroquine) S Inhaled levodopa

Take home messages 1. Medications for PD 2. Don t forget the non-motor symptoms 3. Alternative treatments 4. It s not all about medications

Non-motor symptoms

IMPORTANT Unidentified or untreated non-motor symptoms contribute to poorer quality of life and poorer motor function overall

Urinary, bowel, sexual dysfunction

Postural hypotension WHY TREATMENT S Parkinson s disease S Reduce causative meds S levodopa/dopamine agonist S High salt diet S Other comorbid conditions S Stockings S Other medications S Domperidone S Other meds

Mood Not just sad often irritability Be open and aggressive in treating mood disorders If mood is left untreated, motor symptoms are difficult to treat GREATEST DETERMINANT OF QoL

Cognitive Issues S Not Alzheimer s S Problems: Multi-tasking, visuospatial, executive function S Requires regular assessment Cholinesterase inhibitors are beneficial for select patients

Off Non-motor symptoms S NMS can cycle just as motor symptoms do with OFF times S Eg: off-anxiety, off-sweating S Approach is to reduce the off time

Take home messages 1. Medications for PD 2. Don t forget the non-motor symptoms 3. Alternative treatments 4. It s not all about medications

QUESTION S How many take a non-prescribed drug to help with PD?

Alternative treatments S Coenzyme Q10 S Creatine S Vitamin E S Vitamin D S Mucuna puriens S Caffeine

Alternative treatments S Medical marijuana S S S S anecdotally up to 45% found benefit few controlled studies not shown helpful for tremor or dyskinesias s/e

Take home messages 1. Medications for PD 2. Don t forget the non-motor symptoms 3. Alternative treatments 4. It s not all about medications

QUESTION S What forms of exercise are good for Parkinson s disease? Essentially, all right answers

Drugs aren t everything

Resources S www.parkinson.ca (Parkinson Society Canada) S www.parkinson.bc.ca (Parkinson Society BC) S www.parkinsons.org (National Parkinson s Foundation, USA) S www.pdf.org (Parkinson s disease foundation)

THANK YOU